IL249652B - Crystalline methyloxime -ohydroxymethyl)-1-[(2'-methyl 1,1'-bephenyl-4-yl)carbodyl]pyrrolidine-3-one)-5-(s5, z3) useful in methods for treating conditions related to the activity of the ot-r - Google Patents
Crystalline methyloxime -ohydroxymethyl)-1-[(2'-methyl 1,1'-bephenyl-4-yl)carbodyl]pyrrolidine-3-one)-5-(s5, z3) useful in methods for treating conditions related to the activity of the ot-rInfo
- Publication number
- IL249652B IL249652B IL249652A IL24965216A IL249652B IL 249652 B IL249652 B IL 249652B IL 249652 A IL249652 A IL 249652A IL 24965216 A IL24965216 A IL 24965216A IL 249652 B IL249652 B IL 249652B
- Authority
- IL
- Israel
- Prior art keywords
- methyloxime
- pyrrolidin
- biphenyl
- hydroxymethyl
- carbonyl
- Prior art date
Links
- OLUJSZLBWZWGJT-KOXKPCSVSA-N [(2s,4e)-2-(hydroxymethyl)-4-methoxyiminopyrrolidin-1-yl]-[4-(2-methylphenyl)phenyl]methanone Chemical compound C1C(=N/OC)/C[C@@H](CO)N1C(=O)C1=CC=C(C=2C(=CC=CC=2)C)C=C1 OLUJSZLBWZWGJT-KOXKPCSVSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020076P | 2014-07-02 | 2014-07-02 | |
| PCT/EP2015/062881 WO2016000920A1 (en) | 2014-07-02 | 2015-06-10 | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL249652A0 IL249652A0 (en) | 2017-02-28 |
| IL249652B true IL249652B (en) | 2021-09-30 |
Family
ID=53434312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL249652A IL249652B (en) | 2014-07-02 | 2016-12-19 | Crystalline methyloxime -ohydroxymethyl)-1-[(2'-methyl 1,1'-bephenyl-4-yl)carbodyl]pyrrolidine-3-one)-5-(s5, z3) useful in methods for treating conditions related to the activity of the ot-r |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9718772B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3164384B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2017519015A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102470283B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN114105850A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015283133B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2953722C (cg-RX-API-DMAC7.html) |
| EA (2) | EA201891873A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2774789T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL249652B (cg-RX-API-DMAC7.html) |
| MX (1) | MX371068B (cg-RX-API-DMAC7.html) |
| UA (1) | UA122210C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016000920A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| WO2016000920A1 (en) | 2014-07-02 | 2016-01-07 | ObsEva SA | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
| UA125118C2 (uk) | 2016-01-04 | 2022-01-12 | Обсева С.А. | Альфа-аміноестери карбоксамідного похідного гідроксипропілтіазолідину та їх сольова форма, кристалічна поліморфна форма |
| AU2017300026B2 (en) * | 2016-07-21 | 2023-07-13 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| WO2021043726A1 (en) | 2019-09-03 | 2021-03-11 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| JP7083793B2 (ja) * | 2019-09-10 | 2022-06-13 | Ｊｆｅケミカル株式会社 | パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法 |
| CA3167121A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
| EP4313061A4 (en) * | 2021-03-31 | 2025-03-05 | The Board of Trustees of the Leland Stanford Junior University | FORMULATIONS FOR PROLONGATION OF GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU120988A (en) | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| YU183988A (en) | 1988-09-30 | 1990-08-31 | Lek Tovarna Farmacevtskih | Process for preparing dispersion pills of dihydroergotoxine |
| US5089043A (en) | 1989-11-09 | 1992-02-18 | Shionogi & Co., Ltd. | Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides |
| US5889001A (en) | 1993-07-29 | 1999-03-30 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| JP3534903B2 (ja) | 1995-06-09 | 2004-06-07 | 鐘淵化学工業株式会社 | １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法 |
| GB9603699D0 (en) | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| CZ300558B6 (cs) | 1999-12-09 | 2009-06-17 | Reckitt Benckiser Healthcare (Uk) Limited | Tabletová kompozice nesteroidního protizánetlivého léciva a zpusob její prípravy |
| US7018988B2 (en) | 2000-03-27 | 2006-03-28 | Applied Research Systems Ars Holding N.V. | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors |
| JP2003528854A (ja) | 2000-03-27 | 2003-09-30 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 医薬として活性なピロリジン誘導体 |
| US6821620B2 (en) | 2000-07-13 | 2004-11-23 | Nitto Denko Corporation | Cleaning sheet, conveying member using the same, and substrate processing equipment cleaning method using them |
| ES2303854T3 (es) | 2001-03-20 | 2008-09-01 | Laboratoires Serono Sa | Derivados de ester de pirrolidina con actividad moduladora de oxitocina. |
| KR200245627Y1 (ko) * | 2001-05-15 | 2001-10-15 | 김병두 | 전기 가열부재가 부착된 냄비 |
| HUP0400238A2 (hu) | 2001-06-18 | 2004-07-28 | Applied Research Systems Ars Holding N.V. | Pirrolidin-oxadiazol- és tiadiazolszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények |
| JP2003192582A (ja) | 2001-12-12 | 2003-07-09 | Merck Patent Gmbh | ナプロキセンナトリウムを含む速放性錠剤 |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| DE602004024170D1 (de) | 2003-02-27 | 2009-12-31 | Merck Serono Sa Coinsins | Pyrrolidin-derivate als oxytocin antagonisten |
| BRPI0508059A (pt) | 2004-02-26 | 2007-07-17 | Applied Research Systems | método para preparação de pirrolidina oximas |
| GB2411355B (en) | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| EP1879572B1 (en) | 2005-05-10 | 2011-05-04 | Ferring B.V. | Use of antagonists of oxytocin and/or vasopressin in assisted reproduction |
| JP2008189732A (ja) | 2007-02-01 | 2008-08-21 | Fujifilm Corp | セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置 |
| CA2703501C (en) | 2007-10-01 | 2017-06-13 | Laboratorios Lesvi, S.L. | Orodispersible tablets |
| US9201077B2 (en) | 2009-07-27 | 2015-12-01 | Colorado State University Research Foundation | Direct enzyme immunoassay for measurement of serum progesterone levels |
| EP2922475A1 (en) | 2012-11-26 | 2015-09-30 | Ferring BV | Method and system for diagnosing uterine contraction levels using image analysis |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| WO2016000920A1 (en) | 2014-07-02 | 2016-01-07 | ObsEva SA | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
| PL3037101T3 (pl) | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
-
2015
- 2015-06-10 WO PCT/EP2015/062881 patent/WO2016000920A1/en not_active Ceased
- 2015-06-10 US US14/735,215 patent/US9718772B2/en active Active
- 2015-06-10 CN CN202111228955.9A patent/CN114105850A/zh active Pending
- 2015-06-10 EP EP15730094.8A patent/EP3164384B1/en active Active
- 2015-06-10 AU AU2015283133A patent/AU2015283133B2/en active Active
- 2015-06-10 CN CN202111229040.XA patent/CN114105851A/zh active Pending
- 2015-06-10 ES ES15730094T patent/ES2774789T3/es active Active
- 2015-06-10 CN CN201580047177.XA patent/CN106795110A/zh active Pending
- 2015-06-10 EA EA201891873A patent/EA201891873A1/ru unknown
- 2015-06-10 JP JP2016573776A patent/JP2017519015A/ja active Pending
- 2015-06-10 UA UAA201700678A patent/UA122210C2/uk unknown
- 2015-06-10 EP EP19204954.2A patent/EP3753921A1/en active Pending
- 2015-06-10 KR KR1020177001267A patent/KR102470283B1/ko active Active
- 2015-06-10 CA CA2953722A patent/CA2953722C/en active Active
- 2015-06-10 EA EA201790080A patent/EA031353B1/ru unknown
- 2015-06-10 MX MX2016016751A patent/MX371068B/es active IP Right Grant
-
2016
- 2016-12-19 IL IL249652A patent/IL249652B/en unknown
-
2017
- 2017-05-25 US US15/604,816 patent/US10752583B2/en active Active
-
2020
- 2020-11-09 JP JP2020186785A patent/JP2021038236A/ja active Pending
-
2022
- 2022-11-18 JP JP2022184804A patent/JP2023018037A/ja active Pending
-
2024
- 2024-10-18 JP JP2024182585A patent/JP2025013885A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9718772B2 (en) | 2017-08-01 |
| KR102470283B1 (ko) | 2022-11-23 |
| US20160002160A1 (en) | 2016-01-07 |
| EA201891873A1 (ru) | 2019-04-30 |
| UA122210C2 (uk) | 2020-10-12 |
| EA031353B1 (ru) | 2018-12-28 |
| ES2774789T3 (es) | 2020-07-22 |
| EP3753921A1 (en) | 2020-12-23 |
| EA201790080A1 (ru) | 2017-06-30 |
| AU2015283133A1 (en) | 2017-02-16 |
| US20170320822A1 (en) | 2017-11-09 |
| JP2021038236A (ja) | 2021-03-11 |
| CN114105851A (zh) | 2022-03-01 |
| IL249652A0 (en) | 2017-02-28 |
| CA2953722C (en) | 2022-09-13 |
| CN114105850A (zh) | 2022-03-01 |
| JP2017519015A (ja) | 2017-07-13 |
| EP3164384A1 (en) | 2017-05-10 |
| MX2016016751A (es) | 2017-08-08 |
| JP2025013885A (ja) | 2025-01-28 |
| MX371068B (es) | 2020-01-15 |
| US10752583B2 (en) | 2020-08-25 |
| EP3164384B1 (en) | 2019-12-04 |
| WO2016000920A1 (en) | 2016-01-07 |
| CA2953722A1 (en) | 2016-01-07 |
| KR20170023961A (ko) | 2017-03-06 |
| AU2015283133B2 (en) | 2019-05-16 |
| CN106795110A (zh) | 2017-05-31 |
| JP2023018037A (ja) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249652A0 (en) | Crystalline methyloxime -ohydroxymethyl)-1-[(2'-methyl 1,1'-bephenyl-4-yl)carbodyl]pyrrolidine-3-one)-5-(s5, z3) useful in methods for treating conditions related to the activity of the ot-r | |
| IL267798B (en) | Human antibodies to pd-1 | |
| IL249358A0 (en) | Non-woven combed staple fibers | |
| IL247427B (en) | A chemical agricultural preparation for the treatment of plants | |
| ZA201702799B (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| SG10201911996RA (en) | Process to produce modified clay, modified clay produced and use thereof | |
| PL3102554T3 (pl) | Konwersja 2,3-butanodiolu do butadienu | |
| PL3235494T3 (pl) | Preparat transdermalny zawierający donepezil jako składnik aktywny | |
| PT3044206T (pt) | (3z,5s)-5-(hidroximetil)-1-[(2¿-metil-1,1¿-bifenil-4-il)carbonil)pirrolidin-3-ona o-metiloxima como oxitocina/vasopressina via recetores antagonistas para o tratamento de parto prematuro | |
| HK1243430A1 (zh) | 通过施用il-6r拮抗剂治疗乾眼病的方法 | |
| EP3518915A4 (en) | ALPHA KETOBUTYRATE, ALPHA KETOGLUTARATE AND 2-HYDROXYBUTYRATE FOR STIMULATING HAIR GROWTH | |
| IL264353A (en) | A process for providing antimicrobial treatment to nonwoven fabrics | |
| GB201418071D0 (en) | Improvement in or relation to fishing | |
| PL3187258T3 (pl) | Ulepszenia w reaktorach lub z nimi związane | |
| GB201509482D0 (en) | Apparatus to derive energy from trees | |
| GB2532335B (en) | Improvements in or relating to ploughing tines | |
| GB201505737D0 (en) | Improvements in or relating to carbon capture | |
| GB201405174D0 (en) | Improvements in or relating to guttering | |
| GB2540881B (en) | Improvements relating to scaffolding ties | |
| IN2014MU00127A (cg-RX-API-DMAC7.html) | ||
| TH1601002801A (th) | วิธีผลิต 2, 3-บิวเทนไดออล | |
| GB201413232D0 (en) | Device to manage re-usable tissues | |
| GB201506641D0 (en) | Improvements in or relating to treatment for bruising | |
| TH1501005042B (th) | วิธีการสำหรับการควบคุมราชนิดเส้นใยก่อโรคพืช นอกเหนือจากจุลชีพกลุ่มโอโอไมซีท | |
| GB201400377D0 (en) | Methods relating to wool treatment |